|
|
|
IIb IIIa Inhibitors
|
Ib/IIIa inhibitors can help to prevent the occurrence of restenosis after some catheterization procedures. For more information, browse through our articles below on IIa/IIIb inhibitors. |
|
|
The ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) Trial: What?s the Next Step for Bivalirudin After REPLACE-2?
Everything starts in the emergency room when the patients present, and they will undergo one of three options: 1. The current standard, which is a heparin (in this case, the low-molecular weight heparin enoxaparin) and a IIb/IIIa inhibitor; 2. Bivalirudin plus a IIb/IIIa inhibitor, or; 3. Bivalirudin alone. There are three ...
|
Benefits & Controversies: The REPLACE-2 Trial
Basically, REPLACE-2 demonstrated that bivalirudin was as effective as heparin-IIb/IIIa in preventing ischemic complications, but with significantly less bleeding. The trial was a randomized, double-blind trial of bivalirudin versus heparin plus a IIb/IIIa inhibitor in patients undergoing PCI.
|
Article Commentary: One Institution's Experience with Bivalrudin
4. The most expensive drugs to use (per the institution's pricing) was the combination of bivalirudin and IIb/IIIa inhibitors, but only 39 out of 147 patients received both bivalirudin and IIb/IIIa inhibitors. 6. Bivalirudin and IIb/IIIa inhibitors were more expensive than heparin and IIb/IIIa inhibitors; however, the majority of patients receiving bivalirudin do not get IIb/IIIa inhibitors, whereas the majority of patients receiving heparin also received IIb/IIIa inhibitors. If it is an ...
|
Angioplasty in the Diabetic Patient
Angioplasty in the Diabetic Patient Feature: Angioplasty in the Diabetic Patient - Eric Van Belle, MD, Akram Chmaït, MD, Christophe Bauters, MD, Jean-Marc Lablanche, MD, Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, Lille Cedex, France ABSTRACT: Patients with diabetes have an increased risk of coronary artery disease, and are at an increased risk of mortality and morbidity with coronary revascularization procedures. Outcome of coronary bypass surgery versus coronary ...
|
The TENACITY Trial
Studying a higher bolus dose of tirofiban than in TARGET, this large-scale, randomized trial includes abciximab, and combines each IIb/IIIa inhibitor with either bivalirudin or heparin.
|
Clinical and Industry News
s lifetime heart disease risk, not just short-term risk, according to updated American Heart Association guidelines. Current guidelines recommend the use of Gp IIb/IIIa inhibitors in certain patients with ACS undergoing an invasive strategy, either administered upstream prior to angiography in all patients or initiated in the catheterization laboratory selectively to patients undergoing PCI. The detailed solutions developed by a special Joint Commission Expert Roundtable focus on making ...
|
In Brief: Original Research
Abstracts from the Journal of Invasive Cardiology
|
Medical Management is the Only Rational Approach
?Early conservative treatment is not bad. We can effectively manage the majority of unstable angina cases with aggressive medical treatment.?
|
The Role of Outcomes Research in Reducing Bleeding After Percutaneous Coronary Intervention
Complicating events, particularly bleeding events that occur post-procedurally in patients undergoing percutaneous coronary intervention (PCI) tend to be underestimated and under-recognized. A system that serves to track these complications can increase awareness and hence treatment and prevention. We performed this study to assess true rates of post-PCI complications at our institution, as well as the impact of using bivalirudin (Angiomax®, The Medicines Company, Parsippany, NJ) instead of heparin for anticoagulation during PCI.
|
CEU OFFERING: Advances in Adjunctive Pharmacotherapy for Patients Undergoing PCI
The following CEU activity is supported by an unrestricted educational grant from Eli Lilly and Company.
|
|
|
|
|
|
|
|
On Demand Medical Education
|
|
|
|
|
